Evaluation of Antioxidant Activity and Histopathological Changes Occurred by the Oral Ingestion of CuO Nanoparticles in Monosodium Urate Crystal-Induced Hyperuricemic BALB/c Mice

Kiyani, Mubin Mustafa; Butt, Maisra Azhar; Rehman, Hamza; Mustafa, M. G.; Sajjad, Abdul Ghafoor; Shah, Syed Sajid Hussain; Mahmood, Tariq; Bokhari, Syed Ali Imran

doi:10.1007/s12011-021-02615-3

Cited by 6 publications

(9 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All studies [16, 17, 20-25, 32, 33] that met the inclusion and exclusion criteria were published from 2019 to 2022 with 30 to 140 animals in each study. Four studies [16,17,32,33] were on metal oxide (CuO, ZnO, and FeO), four studies [20][21][22]25] were on non-metallic substances (PLR, AFI, turmeric, GsRb1), and two studies [23,24] were on biologically active substances (IL-1Ra and uricase). Five studies [16,17,21,32,33] used BALB/c mice, four studies [20,22,23,25] used Sprague Dawley (SD) rats, and only one study [24] used the Institute of Cancer Research (ICR) mice.…”

Section: Characteristics Of the Included Studiesmentioning

confidence: 99%

“…Four studies [16,17,32,33] were on metal oxide (CuO, ZnO, and FeO), four studies [20][21][22]25] were on non-metallic substances (PLR, AFI, turmeric, GsRb1), and two studies [23,24] were on biologically active substances (IL-1Ra and uricase). Five studies [16,17,21,32,33] used BALB/c mice, four studies [20,22,23,25] used Sprague Dawley (SD) rats, and only one study [24] used the Institute of Cancer Research (ICR) mice. Among the 10 studies included, five studies [20,[22][23][24][25] included only male animals, and the remaining five studies [16,17,21,32,33] included both male and female animals.…”

Section: Characteristics Of the Included Studiesmentioning

confidence: 99%

“…Five studies [16,17,21,32,33] used BALB/c mice, four studies [20,22,23,25] used Sprague Dawley (SD) rats, and only one study [24] used the Institute of Cancer Research (ICR) mice. Among the 10 studies included, five studies [20,[22][23][24][25] included only male animals, and the remaining five studies [16,17,21,32,33] included both male and female animals. All studies included in this study were quasi-experiments.…”

Section: Characteristics Of the Included Studiesmentioning

confidence: 99%

“…Metal oxide nanoparticles include copper oxide nanoparticles (CuO-NPs), zinc oxide nanoparticles (ZnO-NPs), and iron oxide nanoparticles (FeO-NPs). Among them, CuO-NPs can reduce oxidative stress [16], ZnO-NPs can inhibit the synthesis of mRNA expression of inflammatory cytokines [17], FeO-NPs can reduce inflammation [18]. Moreover, for non-metallic substances encapsulated in nanoparticles, Puerariae lobatae Radix (PLR) has analgesic and anti-inflammatory effects [19], Aurantii fructus immaturus (AFI) is often used in the treatment of inflammatory and metabolic diseases [20], turmeric can relieve inflammation and pain [21], and Ginsenoside Rb1 (GsRb1) can reduce inflammatory cytokines and oxidative stress levels [22].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Effect of nanoparticles on gouty arthritis: a systematic review and meta-analysis

Zhu

Niu

Zhou

et al. 2023

BMC Musculoskelet Disord

View full text Add to dashboard Cite

Objective The purpose of this study was to explore the effects of nanoparticles on gouty arthritis, and to provide evidence for the preclinical application of nanoparticles in gouty arthritis and ideas for nanomedicine improvement for nanoparticle researchers. Methods Five databases including the Cochrane Library, PubMed, Scopus, Web of Science, and Embase were searched for eligible studies until April 2022. The quality of the selected studies was assessed by SYRCLE’s risk of bias (RoB) tool, and the random-effects model was used to calculate the overall effect sizes of weighted mean differences (WMD). Results Ten studies met the inclusion criteria. Results showed that nanoparticles were effective in reducing uric acid levels (WMD: -4.91; 95% confidence interval (CI): − 5.41 to − 4.41; p < 0.001), but were not better than allopurinol (WMD: -0.20; 95% CI: − 0.42 to 0.02; p = 0.099). It was worth noting that the nanoparticles were safer than allopurinol. Subgroup analyses indicated that nanoparticle encapsulated substance, animal species, nanoparticle dosage, animal quantity, and animal gender were all sources of heterogeneity. Conclusion The nanoparticles are safe medications for gouty arthritis which can effectively reduce uric acid levels in rodents. Although the results are still uncertain, it is expected to have certain clinical application value. The nanoparticles may be the preclinical medications for gouty arthritis in the future.

show abstract

Section: Characteristics Of the Included Studiesmentioning

confidence: 99%

Section: Characteristics Of the Included Studiesmentioning

confidence: 99%

Section: Characteristics Of the Included Studiesmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Effect of nanoparticles on gouty arthritis: a systematic review and meta-analysis

Zhu

Niu

Zhou

et al. 2023

BMC Musculoskelet Disord

View full text Add to dashboard Cite

show abstract

“…Furthermore, nanoparticles strategies are adopted to ameliorate oxidative stress in gouty pathology. 28 , 29 Still, the management of hyperuricemia and gout disorders is currently a challenging task and since inflammation is an integral etiological component underlying gout pathogenesis, and therefore it must be considered during the development of treatment strategies.…”

Section: Introductionmentioning

confidence: 99%

Carvacrol Alleviates Hyperuricemia-Induced Oxidative Stress and Inflammation by Modulating the NLRP3/NF-κB Pathwayt

Riaz¹,

Kury²,

Atzaz³

et al. 2022

DDDT

View full text Add to dashboard Cite

Purpose Gouty arthritis is generally induced by the accumulation of monosodium urate (MSU) crystals in the joints due to elevated serum uric acid levels, potentially leading to serious pathological disorders such as nephrolithiasis, renal failure, and acute gouty arthritis. In this study, we aimed to validate the anti-gout effects of carvacrol, a phenolic monoterpene. Materials and Methods Male Sprague–Dawley rats were divided into normal saline, disease group by injecting potassium mono-oxonate (PO) at a dose of 250 mg/kg, and three treatment groups, either with carvacrol 20 mg/kg or 50 mg/kg and 10 mg/kg allopurinol. The blood and tissue samples were subsequently collected and analyzed using different biochemical and histopathological techniques. Results Our results revealed a significant increase in the serum levels of oxidative stress-related markers, namely, uric acid and C-reactive protein (CRP), and NLRP3 inflammasome-dependent inflammatory mediators, including nuclear factor kappa B (NF-κB) and tumor necrosis factor-alpha (TNF-α). Carvacrol administration for seven consecutive days exhibited significant anti-hyperuricemic and anti-inflammatory effects in a dose-dependent manner. Notably, the 50 mg/kg carvacrol treatment was observed to produce results similar to the allopurinol treatment. Furthermore, the renal safety of carvacrol was confirmed by the renal function test. Conclusion Carvacrol potentially alleviates hyperuricemia-induced oxidative stress and inflammation by regulating the ROS/NRLP3/NF-κB pathway, thereby exerting protective effects against joint degeneration.

show abstract

Gout therapeutics and drug delivery

Peng,

Li,

Xie

et al. 2023

Journal of Controlled Release

View full text Add to dashboard Cite

Evaluation of Antioxidant Activity and Histopathological Changes Occurred by the Oral Ingestion of CuO Nanoparticles in Monosodium Urate Crystal-Induced Hyperuricemic BALB/c Mice

Cited by 6 publications

References 40 publications

Effect of nanoparticles on gouty arthritis: a systematic review and meta-analysis

Effect of nanoparticles on gouty arthritis: a systematic review and meta-analysis

Carvacrol Alleviates Hyperuricemia-Induced Oxidative Stress and Inflammation by Modulating the NLRP3/NF-κB Pathwayt

Gout therapeutics and drug delivery

Contact Info

Product

Resources

About